详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Metformin as a booster of cancer immunotherapy

61| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA [2]Department of Medicine, Harvard Medical School, Boston, MA 02215, USA [3]Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan [4]Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China [5]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, Sichuan 610072, China [6]Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand [7]Center for Translational Medicine, Faculty of Medicine, Khon Kaen University 40002, Thailand

出处：

DOI：

ISSN：

摘要：

Metformin, a biguanide antidiabetic, has been studied for its repurposing effects in oncology. Although a modest effect was observed in a single-agent regimen, metformin can synergize the anti-tumor effects of other modalities. The promising combination for cancer treatment is with immunotherapy. Despite high efficacy for some cancers, immunotherapy could be limited by modulation of the tumor immune microenvironment and the immune exhaustion of cytotoxic immune cells. Combining immunotherapy with metformin, thus, exerted a rescuing effect of immunotherapy and potentiated the anti-tumor effects of each other. Although not fully understood, metformin shows promoting effects of immunotherapy by several mechanisms. Those proposed mechanisms have been partially proven and are suggested for possible therapeutic strategies for cancer treatment. In this review, a state-of-the-art of metformin's boosting effects on immunotherapy is reviewed and discussed. The future directions for metformin research in preclinical and clinical immunotherapy are also suggested.Copyright © 2023 Elsevier B.V. All rights reserved.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区

医学

小类 | 2 区免疫学 2 区药学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区免疫学 2 区药学

JCR分区：

出版当年[2023]版：

Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子： 4.8 最新[2023版] 5 最新五年平均 4.8 出版当年[2023版] 5 出版当年五年平均 5.6 出版前一年[2022版]

第一作者：

第一作者机构： [1]Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA [2]Department of Medicine, Harvard Medical School, Boston, MA 02215, USA [3]Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan

通讯作者：

通讯机构： [6]Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand [7]Center for Translational Medicine, Faculty of Medicine, Khon Kaen University 40002, Thailand [*1]Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

推荐引用方式(GB/T 7714)：

APA：

MLA：